10/29/2026
Big changes may be coming to peptide regulation, but goals and headlines aren’t law yet.
Here is what peptide operators and compounders need to know before closing out their budget:
Proposed FDA/HHS pathways could introduce:
1. Mandatory adverse event reporting (a massive operational shift for compounding pharmacies).
2. Required certificates of analysis and strict identity/purity verification.
Heightened scrutiny on gray-market and "Research Use Only" (RUO) sellers.
Whether the policy expands access with strict safeguards or tightens existing restrictions, waiting until the final rule drops leaves zero lead time to build systems.
Link in bio to read Melissa Diaz, CPA’s full regulatory & budgeting breakdown.